Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
RAK | Ann: Rakon director retirement and appointment | 02/10/24 | 0 | 52 | |||
|
|||||||
RAK | Ann: Rakon 2024 Annual Meeting Results | 28/08/24 | 0 | 82 | |||
|
|||||||
RAK | Ann: Rakon 2024 Annual Meeting Speeches | 28/08/24 | 0 | 52 | |||
|
|||||||
RAK | Ann: Rakon Annual Meeting 2024 Presentation | 28/08/24 | 0 | 77 | |||
|
|||||||
RAK | Ann: Rakon Releases FY25 Guidance | 28/08/24 | 0 | 99 | |||
|
|||||||
RAK | Ann: No continuous disclosure investigation | 27/08/24 | 0 | 91 | |||
|
|||||||
RAK | Ann: Rakon announces interim CFO and new executive position | 26/08/24 | 0 | 86 | |||
|
|||||||
RAK | Ann: Rakon launches ground-breaking semiconductor chip for space | 01/08/24 | 1 | 338 | |||
|
See All Discussions